Melbourne, Australia, 20th-21st March 2021: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, is joining forces with HealthCert, the number one professional education provider for skin cancer management and treatment, to demonstrate its world-first technology at HealthCert at the Convention and Exhibition Centre in Sydney.

HealthCert International is a global organisation dedicated to achieving better patient outcomes through comprehensive GP education and universal access to diagnosis and treatment. It provides medical and patient education and runs skin cancer centres where patients can access head-to-toe skin checks, lesion diagnosis and treatment, and TeleDermatology to enable quick diagnosis and treatment recommendations on skin cancer and general dermatology cases.

Kevin Scrimshaw (Commercial Director, ANZ), Martina Clark (Territory Business Manager, VIC) and Shannon Whiteley (Territory Business Manager, NSW) from the DermaSensor team will showcase the DermaSensor device, a revolutionary product designed to augment clinicians’ assessments of skin lesions for cancer.

“DermaSensor’s technology helps clinicians quickly and effectively check for skin cancer,” explains Kevin. “The device can assess a lesion in under 30 seconds using optical spectroscopy and machine learning technology and will become a standard tool of the trade in primary care,” he says.

This exciting breakthrough was achieved using Elastic Scattering Spectroscopy. This technology pioneered at Boston University and University College London. It uses light to evaluate cellular and subcellular structures of the skin.

A recent clinical study found that DermaSensor achieved a sensitivity of 100 percent for detecting melanoma and 93 percent for detecting nonmelanoma skin cancer.

The DermaSensor device is low-cost and easy-to-use. It enables healthcare professionals to provide fast and accurate skin lesion assessments to ultimately detect skin cancer earlier and improve outcomes. Its speed and ease of use could improve workflow by extending lesion identification and evaluation to trained team members. The device is already listed with the TGA and is available for sale in Australia.